Oxidative stress and hypertension: Current concepts

Current Hypertension Reports

Volumn 12, Issue 2, 2010, Pages 135-142

  Briones, Ana M ^a   Touyz, Rhian M ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Antioxidants; Blood pressure; Hydrogen peroxide; Inflammation; NADPH oxidase; Superoxide; Vascular remodeling

Indexed keywords

ANGIOTENSIN II; ASCORBIC ACID; CATALASE; CYTOKINE; GLUTATHIONE PEROXIDASE; HEME OXYGENASE 1; HYDROGEN PEROXIDE; NITRIC OXIDE SYNTHASE; NITROUS OXIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOREDOXIN; TOCOPHEROL; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELL GROWTH; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC VARIABILITY; HEART FUNCTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REDOX STRESS; REVIEW; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; ANTIOXIDANTS; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; HYDROGEN PEROXIDE; HYPERTENSION; INFLAMMATION; NADP; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS; SIGNAL TRANSDUCTION; SUPEROXIDES; XANTHINE OXIDASE;

EID: 77953535497     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0100-z     Document Type: Review

References (80)

1. Paravicini TM, Touyz RM: Redox signaling in hypertension. Cardiovasc Res 2006, 71:247-258.
2. Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57:1446-1454.
3. Huang PL: eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009, 20:295-302.
4. Xu S, He Y., Vokurkova M., Touyz RM: Endothelial cells negatively modulate reactive oxygen species generation in vascular smooth muscle cells: role of thioredoxin. Hypertension 2009, 54:427-433.
5. Allen CL, Bayraktutan U: Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009, 4:461-470.
6. Touyz RM: Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 2005, 14:125-131.
7. Guzik TJ, Korbut R., Adamek-Guzik T: Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003, 54:469-487.
8. Haddad JJ: Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal 2002, 14:879-897.
9. Ardanaz N, Pagano PJ: Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med 2006, 231:237-251.
10. Liochev SI, Fridovich I: The effects of superoxide dismutase on H2O2 formation. Free Radic Biol Med 2007, 42:1465-1469.
11. Suvorava T, Kojda G: Reactive oxygen species as cardiovascular mediators: lessons from endothelial-specific protein overexpression mouse models. Biochem Biophys Acta 2009, 1787:802-810.
12. Brown DI, Griendling KK: Nox proteins in signal transduction. Free Radic Biol Med 2009, 47:1239-1253.
13. Gillespie MN, Pastukh V., Ruchko MV: Oxidative DNA modifications in hypoxic signaling. Ann N Y Acad Sci 2009, 1177:140-150.
14. Ebrahimian T, Touyz RM: Thioredoxin in vascular biology: role in hypertension. Antioxid Redox Signal 2008, 10:1127-1136.
15. Harrison DG, Gongora MC: Oxidative stress and hypertension. Med Clin North Am 2009, 93:621-635.
16. Vaziri ND: Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004, 13:93-99.
17. Addabbo F, Montagnani M., Goligorsky MS: Mitochondria and reactive oxygen species. Hypertension 2009, 53:885-892.
18. Peterson JR, Sharma RV, Davisson RL: Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep 2006, 8:232-241.
19. Ponnuchamy B, Khalil RA: Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol 2009, 296:R1001-R1018.
20. Alp NJ, Paolocci N., Champion H.C., Kass DA: Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008, 117:2626-2636.
21. Hulsmans M, Holvoet P: The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med 2009 Nov 28 (Epub ahead of print).
22. Castro MM, Rizzi E., Rodrigues G.J., et al.: Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009, 46:1298-1307.
23. Tabet F, Savoia C., Schiffrin E.L., Touyz RM: Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004, 44:200-208.
24. Touyz RM, Chen X., Tabet F., et al.: Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002, 90:1205-1213.
25. Yang G, Wu L, Jiang B, et al.: H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008, 322:587-590.
26. Suzuki H, DeLano FA, Parks D.A., et al.: Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci U S A 1998, 95:4754-4759.
27. Adlam D, Bendall JK, De Bono JP, et al.: Relationships between nitric oxide-mediated endothelial function, eNOS coupling and blood pressure revealed by eNOS-GTP cyclohydrolase 1 double transgenic mice. Exp Physiol 2007, 92:119-126.
28. Victor VM, Apostolova N., Herance R., et al.: Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondriatargeted antioxidants as potential therapy. Curr Med Chem 2009, 16:4654-4667.
29. Viel EC, Benkirane K., Javeshghani D., et al.: Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2008, 295:H281-H288.
30. Spiekermann S, Schenk K., Hoeper MM: Increased xanthine oxidase activity in idiopathic pulmonary arterial hypertension. Eur Respir J 2009, 34:276-280.
31. Mervaala EM, Cheng ZJ, Tikkanen I., et al: Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 2001, 37:414-418.
32. Laakso J, Mervaala E., Himberg J.J., et al.: Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension 1998, 32:902-906.
33. Sánchez-Lozada L.G., Tapia E., Soto V., et al.: Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 2008, 23:1179-1185.
34. Kanbay M, Ozkara A., Selcoki Y., et al.: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007, 39:1227-1233.
35. Feig DI, Soletsky B., Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008, 300:924-932.
36. Yang J, Kamide K., Kokubo Y., et al.: Associations of hypertension and its complications with variations in the xanthine dehydrogenase gene. Hypertens Res 2008, 31:931-940.
37. Vásquez-Vivar J: Tetrahydrobiopterin, superoxide, and vascular dysfunction. Free Radic Biol Med 2009, 47:1108-1119.
38. Vasquez-Vivar J., Kalyanaraman B., Martasek P., et al.: Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998, 95:9220-9225. (Pubitemid 28506212)
39. Gao YT, Roman LJ, Martásek P, et al.: Oxygen metabolism by endothelial nitric-oxide synthase. J Biol Chem 2007, 282:28557-28565. (Pubitemid 47606027)
40. Cosentino F, Patton S., d'Uscio LV, et al.: Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998, 101:1530-1537.
41. Ozaki M, Kawashima S., Yamashita T., et al.: Overexpression of endothelial nitric oxide synthase attenuates cardiac. hypertrophy induced by chronic isoproterenol infusion. Circ J 2002, 66:851-856.
42. Landmesser U, Dikalov S., Price S.R., et al.: Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003, 111:1201-1209.
43. Lee CK, Han JS, Won K.J., et al.: Diminished expression of dihydropteridine reductase is a potent biomarker for hypertensive vessels. Proteomics 2009, 9:4851-4858.
44. Ceylan-Isik A.F., Guo KK, Carlson E.C., et al.: Metallothionein abrogates GTP cyclohydrolase I inhibition-induced cardiac contractile and morphological defects: role of mitochondrial biogenesis. Hypertension 2009, 53:1023-1031.
45. Sullivan JC, Pollock JS: Coupled and uncoupled NOS: separate but equal? Uncoupled NOS in endothelial cells is a critical pathway for intracellular signaling. Circ Res 2006, 98:717-719.
46. Katusic ZS, d'Uscio LV, Nath KA: Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci 2009, 30:48-54.
47. Leto TL, Morand S., Hurt D., Ueyama T: Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid Redox Signal 2009, 11(10):2607-2619.
48. Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245-313.
49. Brandes RP, Schröder K: Differential vascular functions of Nox family NADPH oxidases. Curr Opin Lipidol 2008, 19:513-518.
50. Sumimoto H: Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J 2008, 275:3249-3277.
51. Nauseef WM: Biological roles for the NOX family NADPH oxidases. J Biol Chem 2008, 283:16961-16965.
52. Guzik TJ, Griendling KK: NADPH oxidases: molecular understanding finally reaching the clinical level? Antioxid Redox Signal 2009, 11:2365-2370.
53. Lassegue B, Clempus RE: Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003, 285:R277-R297.
54. Sedeek M, Hébert RL, Kennedy C.R., et al.: Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens 2009, 18:122-127.
55. Li JM, Shah AM: Intracellular localization and preassembly of the NAD(P)H oxidase complex in cultured endothelial cells. J Biol Chem 2002, 277:19952-19960.
56. Orosz Z, Csiszar A., Labinskyy N., et al.: Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: role of NAD(P)H oxidase activation. Am J Physiol Heart Circ Physiol 2007, 292:H130-H139.
57. Lyle AN, Deshpande NN, Taniyama Y., et al: Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res 2009, 105:249-259.
58. Touyz RM, Schiffrin EL: Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD (P)H oxidase-sensitive pathways. J Hypertens 2001, 19:1245-1254.
59. Landmesser U, Cai H., Dikalov S., et al.: Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40:511-555.
60. Matsuno K, Yamada H., Iwata K., et al.: Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005, 112:2677-2685.
61. Dikalova A, Clempus R., Lassegue B., et al.: Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005, 112:2668-2676. (Pubitemid 41532604)
62. Touyz RM, Mercure C., He Y., et al.: Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 2005, 45:530-537.
63. Jung O, Schreiber JG, Geiger H., et al: gp91phox-containing NAD(P)H oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004, 109:1795-1801.
64. Zhou MS, Adam AG, Jaimes E.A., Raij L: In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension 2003, 42:945-951.
65. Peterson JR, Burmeister MA, Tian X., et al: Genetic silencing of Nox2 and Nox4 reveals differential roles of these NADPH oxidase homologues in the vasopressor and dipsogenic effects of brain angiotensin II. Hypertension 2009, 54:1106-1114.
66. Wilcox CS: Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 2005, 289:R913-R935.
67. Modlinger P, Chabrashvili T., Gill P.S., et al.: RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 2006, 47:238-244.
68. Adler S, Huang H: Oxidant stress in kidneys of spontaneously hypertensive rats involves both oxidase overexpression and loss of extracellular superoxide dismutase. Am J Physiol Renal Physiol 2004, 287:F907-F913.
69. Panico C, Luo Z., Damiano S., et al.: Renal proximal tubular reabsorption is reduced in adult spontaneously hypertensive rats: roles of superoxide and Na+/H+ exchanger 3. Hypertension 2009, 54:1291-1297.
70. Violi F, Sanguigni V., Carnevale R., et al.: Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 2009, 120:1616-1622.
71. Yogi A, Mercure C., Touyz J., et al.: Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension 2008, 51:500-506.
72. Nambiar S, Viswanathan S., Zachariah B., et al.: Oxidative stress in prehypertension: rationale for antioxidant clinical trials. Angiology 2009, 60:221-234.
73. Nabha L, Garbern JC, Buller C.L., Charpie JR: Vascular oxidative stress precedes high blood pressure in spontaneously hypertensive rats. Clin Exp Hypertens 2005, 27:71-82.
74. Sathiyapriya V, Selvaraj N., Nandeesha H., et al.: Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk. Clin Exp Hypertens 2008, 30:367-374.
75. Callera GE, Touyz RM, Teixeira S.A., et al.: ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 2003, 42:811-817.
76. Chen X, Touyz RM, Park J.B., Schiffrin EL: Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001, 38:606-611.
77. Ardanaz N, Yang XP, Cifuentes M.E., et al.: Lack of glutathione peroxidase 1 accelerates cardiac-specific hypertrophy and dysfunction in angiotensin II hypertension. Hypertension 2009, 55:116-123.
78. Ward NC, Hodgson JM, Puddey I.B., et al.: Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med 2004, 36:226-232.
79. Moreno MU, San Jose G, Orbe J, et al.: Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett 2003, 542:27-31.
80. Holowatz LA, Kenney WL: Local ascorbate administration augments NO- and non-NO-dependent reflex cutaneous vasodilation in hypertensive humans. Am J Physiol Heart Circ Physiol 2007, 293:H1090-H1096.